Wedbush Increases Vor Biopharma (NASDAQ:VOR) Price Target to $27.00

Vor Biopharma (NASDAQ:VOR) had its target price increased by analysts at Wedbush from $18.00 to $27.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Wedbush’s target price would indicate a potential upside of 21.02% from the company’s current price.

Several other analysts also recently issued reports on the company. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Weiss Ratings upgraded Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.38.

Vor Biopharma Stock Performance

VOR traded down $1.28 during trading on Wednesday, reaching $22.31. The stock had a trading volume of 439,610 shares, compared to its average volume of 1,067,896. Vor Biopharma has a 1-year low of $6.50 and a 1-year high of $50.20. The stock has a 50 day moving average of $18.00 and a two-hundred day moving average of $15.88.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). Research analysts predict that Vor Biopharma will post -2.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

A number of large investors have recently bought and sold shares of the company. RA Capital Management L.P. boosted its stake in shares of Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after buying an additional 3,422,697 shares during the period. Fcpm Iii Services B.V. grew its stake in Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after acquiring an additional 3,237,714 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in Vor Biopharma during the fourth quarter worth $33,275,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP bought a new position in shares of Vor Biopharma during the 4th quarter worth $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).